Given the protection of empagliflozin on type 2 immunity-driven inflammation and airway remodeling, accompanied by an enhancement of the GLO 1 detoxification pathway, SGLT2 inhibition may offer therapeutic potential for asthma, particularly in metabolic contexts of obesity and diabetes. Here, SLC5A2 is linked to asthma.